Effect of deferoxamine-hydroxyethyl pentafraction starch on free, autogenous full-thickness skin grafts in dogs.
Free, autogenous, full-thickness skin grafting was performed on 10 dogs; 5 dogs were given an iron chelator, deferoxamine-10% hydroxyethyl pentafraction starch (DEF-HES; 50 mg/kg of body weight, IV), and 5 dogs were given 10% hydroxyethyl pentafraction starch (HES) in 0.9% saline solution (5 ml/kg, IV). The percentage of viable graft on day 10 was higher, but not significantly so, in DEF-HES-treated dogs (mean +/- SD, 72.6 +/- 24.8%; median 76.5%) than in HES-treated dogs (mean +/- SD, 46.7 +/- 34.3%; median, 48.8%). A trend for a positive correlation between the percentage of viable graft (on day 10) and the percentage of original graft area (on day 28) was observed in HES- and DEF-HES-treated dogs; this trend was significant in HES-treated dogs (P = 0.012). Both groups had significant positive correlation between percentage of viable graft on day 10 and percentage of haired skin on day 28 (HES, P = 0.000002; DEF-HES, P = 0.0148). A unique finding in DEF-HES treated dogs was the consistent observation of foamy macrophages in the dermis adjacent to the grafts, in deep subcutaneous tissue below the grafts, and in normal dermis.
Hosgood
G
G
Department of Veterinary Clinical Sciences, Louisiana State University, Baton Rouge 70803.
Lewis
D D
DD
Hodgin
E C
EC
Church
D F
DF
Lopez
M K
MK
D000818:Animals; D003676:Deferoxamine / Q000494:pharmacology*; D004285:Dogs / Q000601:surgery*; D006085:Graft Survival / Q000187:drug effects*; D006895:Hydroxyethyl Starch Derivatives / Q000494:pharmacology*; D016038:Skin Transplantation / Q000473:pathology / Q000662:veterinary*
D006895:Hydroxyethyl Starch Derivatives; C068460:hydroxyethyl starch-deferoxamine conjugate; D003676:Deferoxamine